AOD-9604 vs Semaglutide
How they differ
- FDA status. AOD-9604: Not FDA-approved; FDA advised against adding it to the compounding list.1,2,3 Semaglutide: FDA-approved as Ozempic, Rybelsus and Wegovy.4,5,6,7
- Kinds of studies cited. AOD-9604: limited human data. Semaglutide: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | AOD-9604 | Semaglutide |
|---|---|---|
| What it is | A synthetic 16-amino-acid fragment of human growth hormone (residues 177 to 191 plus an added tyrosine), according to FDA’s 2024 evaluation.1 | A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.4 |
| FDA status | Not FDA-approved Not FDA-approved; FDA advised against adding it to the compounding list1,2,3 Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3 | FDA-approved FDA-approved as Ozempic, Rybelsus and Wegovy4,5,6,7 FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.4,5,6,7 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.8 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.8,9 | Not among the six peptides the policy lists.8 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.3 | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 140 ClinicalTrials.gov records and 108 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 2December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 5Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 10FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 11FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026